Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab impact on walking ability in relapsing-remitting multiple sclerosis
2009-009503-19Phase 4Completed
- Sponsor
- Biogen
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Evolution of walking abilities over 1 year. Started May 2009; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-009503-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009503-19.